Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

Roche and Flare Therapeutics enter oncology partnership worth over $1.8bn

The companies will aim to discover small molecule treatments aimed at previously undrugged transcription factor targets

- PMLiVE

AstraZeneca/Merck’s Koselugo shows promise in adults with neurofibromatosis type 1

The rare genetic condition affects an estimated 1.7 million people globally

- PMLiVE

J&J’s nipocalimab granted FDA breakthrough designation for Sjögren’s disease

The chronic autoimmune disease affects approximately four million people globally

- PMLiVE

Getting to the Heart of the Matter: Medscape Education at AHA 2024!

Come join Medscape Education at the American Heart Association (AHA) 2024 Scientific Sessions in Chicago, IL, from November 16-18 — a dynamic event packed with cutting-edge cardiology education that you...

Medscape Education

- PMLiVE

Novavax announces FDA clinical hold lift on phase 3 COVID-19/flu vaccine study

The serious adverse event reported was found to be unrelated to the vaccine

- PMLiVE

Ogilvy appoints Mario Muredda as global chief executive officer of Ogilvy Health

Muredda most recently served as president of marketing at Avalere Health

OPEN Health Presents First Collection of Research Backed by Scientific Buyout Fund to Foster Research and Development

OPEN Health Presents First Collection of Research Backed by Scientific Buyout Fund to Foster Research and Development

OPEN Health is excited to announce the upcoming presentation of a collection of research supported by its Scientific Buyout Program. This initiative empowers our team members to dedicate time toward...

OPEN Health

- PMLiVE

FDA approves Autolus Therapeutics’ Aucatzyl to treat acute lymphoblastic leukaemia

Approximately 8,400 adults are diagnosed with the aggressive blood cancer every year in the US and EU

- PMLiVE

J&J submits EU and US applications for subcutaneous Darzalex in smouldering multiple myeloma

The early precursor of active disease accounts for 15% of all newly-diagnosed multiple myeloma cases

Daiichi Sankyo logo

Daiichi Sankyo enters $300m licensing deal with Alteogen to develop subcutaneous Enhertu

The company will use Alteogen’s hybrozyme technology to advance the formulation

- PMLiVE

AstraZeneca/Amgen’s Tezspire shows promise in phase 3 CRSwNP trial

The severe asthma drug met both of the late-stage study’s co-primary endpoints

- PMLiVE

WHO announces priority endemic pathogens for urgent vaccine development

The study identifies the 17 pathogens that regularly cause diseases in communities

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links